论文部分内容阅读
目的探讨自体腹水浓缩回输腹腔联合多巴胺在治疗肝硬化顽固性腹水中的应用价值。方法对51例肝硬化顽固性腹水患者在常规治疗基础上,加用自体腹水浓缩回输腹腔联合多巴胺治疗,评价其临床疗效及并发症。结果51例肝硬化顽固性腹水患者应用自体腹水浓缩回输腹腔联合多巴胺治疗,有效42例,总有效率达82.35%;对比单纯自体腹水浓缩回输腹腔治疗33例,有效23 例,总有效率69.70%,两组有效率差异有显著性,P<0.05。且两组治疗后内生肌酐清除率差异亦有显著性,P<0.05。结论自体腹水浓缩回输腹腔联合多巴胺治疗肝硬化顽固性腹水不仅见效快,且安全稳定,值得推广应用。
Objective To investigate the value of autologous ascites concentrated transfusion abdominal combined with dopamine in treatment of refractory cirrhosis and ascites. Methods Fifty-one patients with cirrhosis and refractory ascites were treated with autologous ascites concentration and transfusion combined with dopamine. The clinical efficacy and complications were evaluated. Results 51 cases of patients with cirrhosis and refractory ascites were treated with autologous ascites concentrated transfusion of abdominal combined with dopamine, effective in 42 cases, the total effective rate was 82.35%; compared with the simple autologous ascites concentrated transfusion abdominal treatment of 33 cases, effective in 23 cases, The effective rate was 69.70%, there was significant difference between the two groups, P <0.05. There was also significant difference in endogenous creatinine clearance between the two groups (P <0.05). Conclusion It is not only quick, safe and stable to treat ascites caused by cirrhosis of liver cirrhosis, but also to be popularized and applied.